Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

In vivo double knockout CAR-T screen identifies synergistic gene pairs that enhance anti-tumor immunity

ABSTRACT: Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematological malignancies. However, its efficacy is hindered by multifaceted negative regulatory mechanisms intrinsic to T cells. Here we perform a large-scale high-throughput in vivo double-knockout (DKO) CRISPR screen in human CAR-T cells, and identify multiple DKO gene pairs that are both effective and synergistic. The top pair NR4A1_SOCS3 DKO has multiple favorable immunological features. Whole-transcriptome profiling and in vivo single cell RNA sequencing reveal that NR4A1_SOCS3 DKO specifically upregulated metabolic pathways in CAR-T cells, which was demonstrated to have significant higher metabolic fitness and mitochondria activities. NR4A1_SOCS3 DKO CAR-T or T cells exhibit exceptionally potent anti-tumor efficacy long-term tumor control across different tumor models, without compromising safety features. NR4A1_SOCS3 DKO outperforms other T/CAR-T cell genetic modifications such as REGNASE1 KO, MED12 KO, RASA2 KO, TRAF6 KO and PD1_CTLA4 DKO. These data demonstrate high-throughput DKO screening for rapid discovery of combination targets, and establish NR4A1_SOCS3 as promising joint intracellular checkpoints to engineer high-performance CAR-T therapies against cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE335215 | GEO | 2026/06/23

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

In vivo double knockout CAR-T screen identifies synergistic gene pairs that enhance anti-tumor immunity [scRNA-seq]

Project description:Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematological malignancies. However, its efficacy against solid tumors is hindered by multifaceted negative regulatory mechanisms intrinsic to T cells. Although single gene screens have been performed in T cells, such studies cannot provide causality for the complex genetic interactions governing T cell function. To systematically discover genetic interactions that are critical for CAR-T cell’s anti-tumor immunity, here, we perform a high-throughput in vivo double-knockout (DKO) CRISPR screen in human CAR-T cells and identify multiple DKO gene pairs that are both effective and synergistic. All five top-scoring DKO hits are validated to promote CAR-T cell activation, cytotoxicity, degranulation, effector cytokine production, and memory formation, and reduce exhaustion. Mechanistically, these DKOs enhance calcium influx, phospho-ERK, NF-κB and NFAT/AP-1 signaling. Among these hits, NR4A1_SOCS3 DKO has multiple favorable immunological features and showcases the most robust phenotypes. NR4A1_SOCS3 DKO CAR-T cells show potent in vivo anti-tumor efficacy and markedly enhanced infiltration as compared to both single gene knockouts, without increase in safety risk. Whole-transcriptome profiling and single cell RNA sequencing of tumor-infiltrating CAR-T cells reveal that NR4A1_SOCS3 DKO specifically enhanced metabolic fitness of CAR-T cells, rendering them exceptionally potent in long-term tumor control in an orthotopic model, superior to both single gene knockouts and the PD1_CTLA4 dual-checkpoint DKO benchmark. These data together demonstrate the efficacy of high-throughput DKO screening to rapidly uncover critical genetic interactions within T cells, and discover NR4A1_SOCS3 as promising joint intracellular checkpoints to engineer high-performance CAR-T therapies against solid tumors.

2026-06-17 | GSE272886 | GEO

In vivo double knockout CAR-T screen identifies synergistic gene pairs that enhance anti-tumor immunity [bulk RNA-seq]

2026-06-17 | GSE272885 | GEO

In vivo double knockout CAR-T screen identifies synergistic gene pairs that enhance anti-tumor immunity [crispr_screen]

2026-06-17 | GSE272884 | GEO

Improved persistence and expanded TPEX formation in Regnase-1 KO CAR T cells is TCF-1-dependent

Project description:transcriptional profiling was performed on Regnase-1 KO CAR and Regnase-1 TCF-1 DKO CAR T cells isolated 7days after co-transfer into tumor bearing mice. TCF-1 deficiency in Regnase-1 KO CAR T cells led to reduced long-term persistence and memory-like phenotype.

2021-04-07 | GSE155020 | GEO

Expression data from WT and MED12 KO SKOV3 and HO8910 cells

Project description:Epithelial ovarian cancer (EOC) is the leading cause of death among all gynecological malignancies due to high rate of disease relapse. Disease relapse in cancer patients after clinical remission are often referred to tumor dormancy. Here we identify the RNA polymerase II transcriptional Mediator subunit 12 (MED12) as an important molecular regulator of tumor dormancy. We found that MED12 knock-out (KO) could induce dormancy of EOC cells in vitro and in vivo. Mechanistically, microarray analysis showed that MED12 KO decreased the expression of EGFR. Hierarchical cluster assays of the differentially expressed genes between MED12 WT and KO single clones of SKOV3 and HO8910 cells.

2018-04-10 | GSE112888 | GEO

B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism [enrichement scRNA-Seq]

Project description:Chimeric antigen receptor (CAR)-T cell therapy has shown promise in treating CD19+ hematological tumors, but some patients fail to respond. Here we used an immune-competent mouse model of B cell acute lymphoblastic leukemia (B-ALL) to assess clonal tumor populations with distinct responses to CAR-T cell therapy. We identified GPR65 as a determinant of tumor responsiveness to CAR-T cell therapy, with high GPR65 expression associated with a complete response. GPR65 KO tumors were resistant to CAR-T treatment in vivo. This was associated with increased tumor VEGFA expression driven by FOXO1 activation and expanded host macrophages. Either depletion of host macrophages or deletion of VEGFA from GPR65 KO tumors restored responsiveness to CAR-T cell treatment. Anti-VEGFa therapy, in combination with CD19-CAR-T, prolongs the survival of GPR65-KO tumor-bearing mice in pre-clinical models. Our results indicate that GPR65 may be a useful biomarker for tumor responsiveness to CAR-T cell therapy and further suggest VEGFA or host macrophages as therapeutic targets to improve CAR-T efficacy.

2025-01-30 | GSE266165 | GEO

B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism [bulk RNA-Seq]

2025-01-30 | GSE266164 | GEO

B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism [RNA-Seq]

2025-01-30 | GSE266240 | GEO

B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism [scRNA-Seq]

2025-01-30 | GSE236031 | GEO

Expression data from SKOV3 KO1#_Vector and SKOV3 KO1#_MED12 rescued cells

2018-04-10 | GSE112887 | GEO